The presence of a pituitary tumor on magnetic resonance imaging confirmed the diagnostic hypothesis.
Results show increased hospital charges, costs and length of stay for patients treated by lower-volume surgeons.
Copeptin represents a novel, early marker for postoperative diabetes insipidus after pituitary surgery.
The FDA has approved pasireotide (Signifor long-acting release) for treatment of acromegaly.
Researchers have discovered a single gene in a region of the X chromosome that may cause excessive growth in children.
The Endocrine Society has issued a clinical practice guideline for the diagnosis and treatment of acromegaly.
Proton irradiation is an effective treatment for functional pituitary adenomas, and hypopituitarism remains the primary adverse effect.
Endocrinology Advisor Articles
- Long-Term Efficacy and Safety of Dapagliflozin for Type 1 Diabetes
- Measuring Time in Range During CGM May Be Useful Outcome Metric for Clinical Trials
- HbA1c Variability in General Population Increases Risk for Cardiovascular Events, All-Cause Mortality
- Safety and Effectiveness of the Most Common Bariatric Procedures Examined
- AHA, ADA Announce Joint Education Initiative to Reduce CVD Deaths in T2D
- High Circulating Prolactin Concentrations May Lower Risk for Type 2 Diabetes
- Online Tool Helps Patients With Advance Care Planning
- Dapagliflozin Lowers Heart Failure Hospitalization Rates in High-Risk Patients With Diabetes
- Direct-Acting Antiviral Therapy Reduced Risk for Incident T2D in Patients With Hepatitis C Infection
- Technological Breakthroughs in Medicine Move Physician-Patient Interactions From The Computer Screen Back to the Exam Room